BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

US inks $1.95B deal with Pfizer, BioNTech for COVID-19 vaccine doses

July 24, 2020 | News

U.S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses



Pfizer Inc. and BioNTech SE have announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government's Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.

Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).

The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses.

Americans will receive the vaccine for free consistent with U.S. government's commitment for free access for COVID-19 vaccines.